2024年1至12月份，华人健康的营业收入构成为：零售占比69.47%，代理占比17.56%，终端集采占比 7.59%，工业生产占比3.65%，其他业务占比1.72%。 截至发稿，华人健康市值为59亿元。 每经AI快讯，华人健康（SZ 301408，收盘价：14.77元）8月15日晚间发布公告称，公司于2025年8月14 日收到股东黄山赛富、腾元投资、长菁投资、苏州赛富出具的《关于合计持股5%以上股东减持时间届 满暨减持结果的告知函》，获悉黄山赛富、腾元投资、长菁投资、苏州赛富减持计划已到期，在减持计 划实施期间，黄山赛富、腾元投资、长菁投资、苏州赛富通过集中竞价及大宗交易的方式合计减持公司 股份约539.89万股，减持股份占公司总股本的比例为1.3497%。 每经头条（nbdtoutiao）——华康股份11亿元并购疑云：收购对象的大客户两年前已深陷债务危机，如 何贡献巨额营收？ （记者 王晓波） ...

证券代码：301408 证券简称：华人健康 公告编号：2025-057 | 股东名称 | 减持期间 | 减持方式 | 减持数量 | 减持价格区间 | 减持均价 | 占总股本 | | --- | --- | --- | --- | --- | --- | --- | | | | | （万股） | （元/股） | （元/股） | 比例 | | 黄山赛富 | 2025 年 5 月 27 日-2025 年 | 集中竞价 交易 | 106.3336 | 12.00-16.09 | 14.20 | 0.2658% | | | 8 月 7 日 | | | | | | | | | 大宗交易 | 45.9000 | 13.08-13.88 | 13.39 | 0.1147% | | 腾元投资 | 2025 年 6 月 26 日-2025 年 | 集中竞价 | 25.4600 | 12.07-16.31 | 14.16 | 0.0636% | | | | 交易 | | | | | | | 7 月 15 日 | 大宗交易 | - | - | - | - | | 长菁投资 | 2025 年 6 月 26 日-2025 年 | 集中竞 ...

Market Performance - The pharmaceutical commercial sector increased by 0.27% on August 15, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] Individual Stock Performance - RunDa Medical (603108) closed at 18.15, up 2.02%, with a trading volume of 228,200 shares and a transaction value of 410 million yuan [1] - Other notable performers included Huaren Health (301408) at 14.77, up 1.79%, and Yixin Pharmacy (002727) at 14.97, up 1.70% [1] - Conversely, Seer Medical (603716) saw a decline of 3.69%, closing at 28.41, with a trading volume of 358,300 shares and a transaction value of 1.017 billion yuan [2] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 199 million yuan from institutional investors, while retail investors saw a net inflow of 162 million yuan [2] - The data indicates that retail investors are more active in the sector compared to institutional investors [2] Detailed Capital Flow for Selected Stocks - For 瑞康医药 (002589), the net inflow from institutional investors was 15.82 million yuan, while retail investors had a net outflow of 18.36 million yuan [3] - RunDa Medical (603108) had a net inflow of 7.52 million yuan from institutional investors, but also saw outflows from retail investors [3] - The overall trend shows that while some stocks attract institutional interest, retail investors are more likely to withdraw their investments [3]

Group 1 - The core viewpoint of the news is that Huaren Health experienced a decline in stock price and trading volume, with significant financing activities indicating high investor interest despite the drop [1] - On August 14, Huaren Health's stock fell by 3.97%, with a trading volume of 232 million yuan, and a net financing purchase of 8.51 million yuan [1] - As of August 14, the total financing and securities lending balance for Huaren Health was 173 million yuan, representing 8.00% of its market capitalization, which is above the 90th percentile of the past year [1] Group 2 - Huaren Health's main business segments include pharmaceutical agency, retail, and terminal procurement, with the revenue composition being 80.25% from Western and Chinese medicines, 4.62% from health products, and 4.00% from medical devices [1] - As of March 31, the number of shareholders for Huaren Health increased by 9.39% to 18,000, while the average circulating shares per person decreased by 8.58% to 8,309 shares [2] - For the first quarter of 2025, Huaren Health reported a revenue of 1.267 billion yuan, a year-on-year increase of 14.71%, and a net profit attributable to shareholders of 61.22 million yuan, up 28.15% year-on-year [2] Group 3 - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3] - As of March 31, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Huaren Health [3]

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is experiencing fluctuations in stock performance and is actively engaging in various e-commerce platforms and innovative technologies to enhance its business operations and growth potential [1][2][3]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and is located in Hefei, Anhui Province. The company primarily engages in pharmaceutical agency, retail, and terminal procurement [7]. - The main revenue composition includes: 80.25% from Chinese and Western medicine, 4.62% from health products, 4.23% from other goods, 4.00% from medical devices, 3.28% from traditional Chinese medicine pieces, 1.89% from specialty raw materials, and 1.72% from other supplementary products [7]. Financial Performance - For the period from January to March 2025, the company achieved a revenue of 1.267 billion yuan, representing a year-on-year growth of 14.71%. The net profit attributable to the parent company was 61.22 million yuan, reflecting a year-on-year increase of 28.15% [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [9]. Market Position and Shareholder Structure - As of March 31, 2025, the number of shareholders reached 18,000, an increase of 9.39% from the previous period. The average circulating shares per person decreased by 8.58% to 8,309 shares [8]. - Alibaba Health, a subsidiary of Alibaba, holds a 7.51% stake in the company, making it the second-largest shareholder [3]. Strategic Initiatives - The company is expanding its presence on major domestic e-commerce platforms, including JD.com, Pinduoduo, and Meituan, in addition to Alibaba's Tmall and Ele.me [2]. - The company is focusing on the integration of artificial intelligence (AI) technologies to enhance operational efficiency and customer experience, including AI medical consultations and customer service applications [2][3]. Technical Analysis - The average trading cost of the stock is 15.03 yuan, with the current stock price approaching a resistance level of 14.53 yuan. A breakthrough of this resistance could signal a potential upward trend [6].

8月13日，沪深两融数据显示，华人健康获融资买入额0.43亿元，居两市第1212位，当日融资偿还额0.20 亿元，净买入2384.79万元。 本文源自：金融界 最近三个交易日，11日-13日，华人健康分别获融资买入0.25亿元、0.32亿元、0.43亿元。 作者：智投君 融券方面，当日融券卖出0.01万股，净卖出0.01万股。 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

Core Viewpoint - The company, Huaren Health, has shown a positive trend in its stock performance and financial metrics, indicating potential growth opportunities in the pharmaceutical sector [1][2]. Financing and Trading Data - On August 12, Huaren Health's stock increased by 0.72%, with a trading volume of 294 million yuan. The financing buy-in amounted to 31.94 million yuan, while the financing repayment was 31.34 million yuan, resulting in a net financing buy of 599,900 yuan [1]. - As of August 12, the total financing and securities balance for Huaren Health was 141 million yuan, representing 6.13% of its market capitalization. This financing balance is above the 90th percentile of the past year, indicating a high level of activity [1]. - In terms of securities lending, on August 12, Huaren Health had no shares sold short, with a total of 0 shares in the lending balance, which is below the 30th percentile of the past year, indicating low short-selling activity [1]. Company Overview - Huaren Health, established on June 29, 2001, is located in Hefei, Anhui Province. The company was listed on March 1, 2023, and primarily engages in pharmaceutical agency, retail, and terminal procurement [1]. - The revenue composition of Huaren Health includes: 80.25% from Western and Chinese medicines, 4.62% from health products, 4.23% from other goods, 4.00% from medical devices, 3.28% from traditional Chinese medicine pieces, 1.89% from specialty raw materials, and 1.72% from other supplementary products [1]. Financial Performance - For the period from January to March 2025, Huaren Health reported a revenue of 1.267 billion yuan, reflecting a year-on-year growth of 14.71%. The net profit attributable to shareholders was 61.22 million yuan, marking a 28.15% increase compared to the previous year [2]. - As of March 31, 2025, the number of shareholders for Huaren Health was 18,000, an increase of 9.39% from the previous period, while the average number of circulating shares per person decreased by 8.58% to 8,309 shares [2]. Dividend and Shareholding - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3]. - As of March 31, 2025, Hong Kong Central Clearing Limited was no longer among the top ten circulating shareholders of Huaren Health [3].

资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药80.25%，保健品4.62%，其他商品4.23%，医疗器械4.00%，中药饮片 3.28%，特色原料药1.89%，其他(补充)1.72%。 截至3月31日，华人健康股东户数1.80万，较上期增加9.39%；人均流通股8309股，较上期减少8.58%。 2025年1月-3月，华人健康实现营业收入12.67亿元，同比增长14.71%；归母净利润6122.23万元，同比增 长28.15%。 分红方面，华人健康A股上市后累计派现8000.20万元。 机构持仓方面，截止2025年3月31日，华人健康十大流通股东中，香港中央结算有限公司退出十大流通 股东之列。 来源：新浪证券-红岸工作室 8月11日，华人健康涨3.18%，成交额2.92亿元。两融数据显示，当日华人健康获融资买入额2522.26万 元，融资偿还3387.05万元，融资净买入-864.78万元。截至8月11日，华人健康融资融券余额合计 ...

融券方面，当日融券卖出0.01万股，净卖出0.01万股。 本文源自：金融界 作者：智投君 8月11日，沪深两融数据显示，华人健康获融资买入额0.25亿元，居两市第1718位，当日融资偿还额0.34 亿元，净卖出864.78万元。 最近三个交易日，7日-11日，华人健康分别获融资买入0.53亿元、0.40亿元、0.25亿元。 ...